Business / Finance

RSS

Targacept reports net loss of $12.4 million for Q2 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the second quarter and six months ended June 30, 2013.

6 Aug 2013

Portage Health inks definitive agreement to form joint venture with LifePoint Hospitals

The Portage Health Board of Directors has signed a definitive agreement to form a joint venture with LifePoint Hospitals. The agreement, which includes $60 million in capital investments over the next 10 years by the new joint venture, would allow Portage Health to expand and enhance its services to better meet the healthcare needs of its communities.

6 Aug 2013

TTY BIOPHARM receives Outstanding Company of the Year award

TTY BIOPHARM was awarded "Outstanding Company of the Year", the highest award given at the Bio Taiwan 2013 Exhibition. At the opening ceremony on July 18, Rong-Jing Lin, Chairman and General Manager of TTY BIOPHARM, received the prize from Ma Ying-jeou, President of Taiwan.

6 Aug 2013

Ensemble Therapeutics initiates research and development collaboration with Novartis

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, today announced the initiation of a two-part research and development collaboration with Novartis.

6 Aug 2013

Life Tech, Raintree Launch Oncology Testing, Patient Data Initiatives

...

6 Aug 2013

New England Biolabs Gains Access To Advanced NGS Library Prep Method

...

From New England Biolabs 6 Aug 2013

Bayer Collaboration Could Net $540M+ For Compugen

...

6 Aug 2013

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

Compugen, Bayer sign collaboration and license agreement for antibody-based cancer immunotherapies

Compugen Ltd. announced today the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators.

5 Aug 2013

MEDNAX acquires Holston Anesthesia Associates

MEDNAX, Inc., today announced the acquisition of Holston Anesthesia Associates, P.C., a physician group practice based in Kingsport, Tenn. The practice will become part of MEDNAX's American Anesthesiology division and is the third Tennessee-based anesthesiology practice to join this division.

5 Aug 2013

Nubreed Nutrition teams up with legendary bodybuilder Lee Priest

Nubreed Nutrition, Inc, a nutritional supplement company focusing on active lifestyles, Nubreed Nutrition is excited to announce the newest athlete to the team, legendary bodybuilder Lee Priest.

3 Aug 2013

ConforMIS expands Series E financing to $167.7 million

ConforMIS, Inc., a privately held medical device company pioneering patient-specific orthopedic implants, announced today it has expanded its Series E financing to $167.7 million with participation from top-tier Sovereign Wealth Funds, Government Investment Funds and Private Equity Funds in the U.S., Europe, Asia and the Middle East.

3 Aug 2013

Music that Matters selects NanoTech to provide technology for its IPTV/OTT music channel

Music that Matters is proud to announce that it has selected NanoTech Entertainment (OTCPINK: NTEK) to provide the technology and backbone for its upcoming IPTV/OTT music channel.

3 Aug 2013

China CDC, Aeras sign MOU to advance research, development of new TB vaccines

With the global tuberculosis epidemic becoming more deadly, costly, and difficult to treat, Chinese Center for Disease Control and Prevention and Aeras today signed a memorandum of understanding to advance research and development of new tuberculosis vaccines. An improved TB vaccine offers the best hope for eliminating this airborne infectious disease that kills 1.4 million people worldwide each year.

3 Aug 2013

PharMerica reports net income of $10.2 million for Q2 2013

PharMerica Corporation, a national provider of pharmacy services, today reported its financial results for the second quarter and six months ended June 30, 2013.

2 Aug 2013

Aviv REIT acquires post-acute and long-term care skilled nursing facility in Kentucky

Aviv REIT, Inc. announced today it has acquired a post-acute and long-term care skilled nursing facility in Kentucky for $9.3 million.

2 Aug 2013

Emergent BioSolutions acquires Bracco Diagnostics' Healthcare Protective Products Division

Emergent BioSolutions Inc. announced today that it has closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. This acquisition, which includes the RSDL (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent's biodefense franchise into the chemical countermeasure market.

2 Aug 2013

Neuland Laboratories Q1 FY 2014 revenues decrease 4% to $20.27 million

Neuland Laboratories Ltd., a pharmaceutical manufacturer providing active pharmaceutical ingredients, complex intermediates and contract manufacturing services to customers located in 85 countries, today announced financial results for the first quarter of fiscal year 2014, ended June 30, 2013.

2 Aug 2013

Toshiba receives order from NIRS for carbon ion radiotherapy system

Toshiba Corporation today announced that it has received an order from Japan's National Institute of Radiological Sciences (NIRS) for the world's first rotating gantry irradiation system with superconducting magnets for a carbon ion radiotherapy system. The system will be installed in a new radiotherapy room that NIRS is constructing at its facility in Chiba, east of Tokyo, in March 2015.

2 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013